8-KCorporate ChangesExhibits & Filings

Elevance Health, Inc. 8-K Report, Bylaw Amendment (Oct 28, 2009)

Filed October 28, 2009For Securities:ELV

Summary

This 8-K filing from WellPoint, Inc. (now Elevance Health) on October 28, 2009, primarily details amendments made to the company's By-Laws on October 23, 2009. These amendments are procedural in nature and aimed at modernizing governance practices. Key changes include the addition of provisions for shareholder meeting procedures, the renaming of the "Presiding Director" role to "Lead Director," and the allowance for electronic submission of proxy materials, aligning with evolving legal frameworks and best practices. While these amendments do not represent a significant shift in the company's financial performance or strategic direction, they are important for corporate governance. Investors interested in the company's structure and shareholder engagement should note these changes. The adoption of electronic proxy submission, in particular, reflects a move towards increased efficiency and potentially broader accessibility for shareholders to receive and act on important company information.

Key Highlights

  • 1WellPoint, Inc. (now Elevance Health) amended its By-Laws on October 23, 2009.
  • 2The amendments were adopted by the Board of Directors.
  • 3New provisions regarding procedures for shareholder meetings have been added.
  • 4The title "Presiding Director" has been officially changed to "Lead Director".
  • 5The By-Laws now permit the electronic submission of proxy materials, where allowed by state law.
  • 6These changes are effective upon adoption by the Board.
  • 7The filing includes the amended By-Laws as an exhibit.

Frequently Asked Questions

The main purpose of this 8-K filing is to report amendments made to WellPoint, Inc.'s By-Laws on October 23, 2009. These amendments are primarily procedural and aimed at enhancing corporate governance.

The key changes include new provisions for shareholder meeting procedures, the renaming of the "Presiding Director" to "Lead Director," and the authorization for electronic submission of proxy materials in compliance with state laws.

These amendments are primarily related to corporate governance and procedural matters. They do not appear to have an immediate direct financial impact on the company's operations or financial statements.

While the filing doesn't explicitly state the reasoning, the change from 'Presiding Director' to 'Lead Director' is often made to align with evolving corporate governance best practices and to more clearly define the responsibilities of this independent board leadership role.